Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

SYMLIN

PRAMLINTIDE ACETATE

Standard Dose
EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SYMLIN is listed in Drugs@FDA under application 021332 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient PRAMLINTIDE ACETATE Form and strength INJECTABLE;SUBCUTANEOUS - EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2019-12-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview SYMLIN is listed in Drugs@FDA under application 021332 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PRAMLINTIDE ACETATE Form and strength INJECTABLE;SUBCUTANEOUS - EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2019-12-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.